MorphoSys, which is licensing antibodies to pharmas and developing its own therapy for lymphoma, announced terms for its US IPO on Monday.
The Planegg, Germany-based company plans to raise $200 million by offering 8.3 million ADSs at a price of $24.12, the as-converted price of its common stock on the Frankfurt Stock Exchange. At $24.12, MorphoSys would command a market value of $3.0 billion. That would make it the largest biotech to list in the US in the past 10 years.
MorphoSys was founded in 1992 and booked $67 million in revenue for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol MOR. Goldman Sachs, J.P. Morgan and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of April 16, 2018.
